Understanding the causes of a rare blood disorder called immune thrombotic thrombocytopenic purpura (iTTP)
Official title: Pathogenesis of thrombotic microangiopathies
Funded at University of Kansas Medical Center · NIH-10904634 · Data updated 2026-11-12
This study is looking into how a serious blood disorder called immune thrombotic thrombocytopenic purpura (iTTP) happens, focusing on the immune system and genetics, to help find better treatments for people living with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kansas Medical Center NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project start | August 15, 2023 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $508,688 |
| NIH project number | 5R01HL164016-02 |
| Project ID | NIH-10904634 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with immune thrombotic thrombocytopenic purpura or those with related blood disorders.
✕Less likely to help
Patients with other types of blood disorders that do not involve autoantibodies against ADAMTS13 may not benefit from this research.
What this research studies
This research investigates the underlying mechanisms of immune thrombotic thrombocytopenic purpura (iTTP), a serious blood disorder caused by autoantibodies against a specific protein called ADAMTS13. The study aims to identify unique molecular signatures in the immune response of patients and explore genetic factors that may contribute to the disease. By utilizing advanced techniques and animal models, researchers hope to uncover new insights into how iTTP develops and progresses. The ultimate goal is to inform the development of innovative treatment strategies for patients suffering from this condition.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options for patients with immune thrombotic thrombocytopenic purpura and similar blood disorders.
How similar studies have gone: Previous research has shown promise in understanding similar autoimmune blood disorders, suggesting that this approach may yield valuable insights.
Where this research is happening
-
University of Kansas Medical Center
Kansas City, United States Active
Researchers
- Principal investigator: Zheng, X. Long — University of Kansas Medical Center
- Study coordinator: Zheng, X. Long
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.